There is no FDA-approved Wegovy pill form. Wegovy is only available as a once-weekly subcutaneous injection at doses of 0.25, 0.5, 1.0, 1.7, and 2.4 mg. The closest oral semaglutide product on the US market is Rybelsus, an FDA-approved daily tablet from Novo Nordisk that is indicated for type 2 diabetes only and not for chronic weight management. Novo Nordisk has higher-dose oral semaglutide tablets in late-stage development for obesity, but those formulations are not yet approved as a Wegovy pill.
What Wegovy Is Today
Wegovy is the brand name Novo Nordisk uses for semaglutide 2.4 mg, a once-weekly subcutaneous injection FDA-approved for chronic weight management in adults and adolescents 12 years and older with obesity (BMI 30 or higher) or overweight (BMI 27 or higher) with at least one weight-related comorbidity. In 2024, the FDA expanded the label to include a cardiovascular risk reduction indication for adults with established cardiovascular disease and overweight or obesity. The current Wegovy prescribing information describes only the injectable formulation.
Why Wegovy Is Not Available as a Pill
Semaglutide is a 31 amino acid peptide. Like other peptides, it is broken down by stomach acid and intestinal enzymes when swallowed in a conventional tablet. To absorb a peptide orally, the formulation needs a permeation enhancer or a delivery technology that protects the molecule and helps it cross the gut wall. The Rybelsus tablet uses sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC) to allow absorption in the stomach. Even with SNAC, oral semaglutide bioavailability is around 1 percent, which is why Rybelsus tablets contain milligrams of drug to deliver a weight-effective exposure equivalent to a much smaller injectable dose.
Rybelsus: The Existing Oral Semaglutide
Rybelsus is the only FDA-approved oral semaglutide tablet in the US. It comes in 3, 7, and 14 mg strengths and is taken once daily on an empty stomach with no more than four ounces of plain water, then food and other medications are held for at least 30 minutes. Rybelsus is approved only for adults with type 2 diabetes; it is not indicated for weight loss. Some clinicians use it off-label for weight management, but the 14 mg ceiling cannot match the semaglutide exposure delivered by 2.4 mg of weekly Wegovy injection. Per the Rybelsus label, the most common adverse reactions are gastrointestinal, similar to the injectable forms.
Wegovy vs Rybelsus at a Glance
| Feature | Wegovy | Rybelsus |
|---|---|---|
| Active Ingredient | Semaglutide | Semaglutide |
| Form | Subcutaneous injection | Oral tablet |
| Frequency | Once weekly | Once daily |
| FDA-Approved Use | Chronic weight management; cardiovascular risk reduction | Type 2 diabetes only |
| Approved Doses | 0.25 to 2.4 mg | 3, 7, 14 mg |
| Food Restriction | None | Empty stomach, then wait 30 minutes |
| Injection Required | Yes | No |
What Novo Nordisk Has in the Pipeline
Novo Nordisk has been studying higher-dose oral semaglutide for weight management in the OASIS phase 3 program. OASIS-1 evaluated 50 mg oral semaglutide once daily in adults with obesity and reported approximately 15 percent weight loss at 68 weeks. Subsequent OASIS trials evaluated 25 mg and additional populations. The company has signaled regulatory submissions to the FDA for an oral weight-management indication. As of this article’s publication, the FDA has not yet approved a higher-dose oral semaglutide for chronic weight management, and Novo Nordisk has not officially branded any future oral product as Wegovy.
What About Compounded “Wegovy Pills”?
Some online vendors and wellness clinics market compounded oral semaglutide as a Wegovy pill alternative. These products are not FDA-approved. During the 2022 to 2024 semaglutide shortage, compounding pharmacies could legally produce certain semaglutide preparations under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. The FDA declared the semaglutide shortage resolved in 2025, narrowing the legal basis for routine large-scale compounding. Even when compounding was permitted, the FDA cautioned against products containing semaglutide salts that have not been evaluated for safety or efficacy. Sublingual or oral compounded preparations face additional bioavailability questions because they typically lack the SNAC permeation enhancer that allows Rybelsus absorption.
Side Effects to Discuss With Your Prescriber
Whether semaglutide is delivered by injection or by tablet, the safety profile is similar. The most common adverse reactions include nausea, diarrhea, vomiting, constipation, abdominal pain, and decreased appetite. Most are dose-related and improve as the dose is escalated slowly. Less common but serious risks include pancreatitis, gallbladder disease, acute kidney injury from dehydration, and a boxed warning for thyroid C-cell tumors observed in rodent studies. Semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. If you are exploring weight management for prediabetes, see our treatment hub and the discussion of A1C levels for context on glucose monitoring.
The Bottom Line
A Wegovy pill does not exist today. The only FDA-approved oral semaglutide is Rybelsus, and it is approved for type 2 diabetes, not weight management. Higher-dose oral semaglutide for obesity is in late-stage development but not yet on pharmacy shelves. If you want the dose-equivalent of Wegovy, the injection remains the only authorized path. If oral options matter to you, ask your prescriber about Rybelsus or wait for the next-generation oral formulation to clear FDA review.
Medical disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication or treatment plan.
